CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...
Full Year 2024 Revenue: $515,000, down from $11 million in 2023.
Q4 2024 Cost of Revenue: $272,000, down from $773,000 in Q4 2023.
Full Year 2024 Cost of Revenue: $1.6 million, down from $2 million in 2023.
Q4 2024 Gross Loss: $108,000, compared to $474,000 in Q4 2023.
Full Year 2024 Gross Loss: $1.1 million, compared to a gross profit of $9 million in 2023.
Q4 2024 Operating Expenses: $3.9 million, down from $4.6 million in Q4 2023.
Full Year 2024 Operating Expenses: $16.1 million, down from $16.5 million in 2023.
Q4 2024 Net Loss: $3.9 million or $0.34 per share, compared to $4.7 million or $0.41 per share in Q4 2023.
Full Year 2024 Net Loss: $16.6 million or $1.45 per share, compared to $7 million or $0.62 per share in 2023.
Cash and Cash Equivalents (Dec 31, 2024): $11.9 million.
Cash Used in Operating Activities (2024): $14.1 million, compared to $2.8 million in 2023.
Cash Used in Investing Activities (2024): $539,000, compared to $1.2 million provided in 2023.
Cash Provided by Financing Activities (2024): $9,000, compared to $1.1 million in 2023.
Warning! GuruFocus has detected 4 Warning Signs with CLGN.
Release Date: March 26, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
CollPlant Biotechnologies Ltd (NASDAQ:CLGN) is advancing its proprietary photocurable dermal filler, which is in the preclinical phase and targets a market valued at approximately $6.3 billion with a 10% compound annual growth rate.
The company has received positive feedback from thought leaders in aesthetic medicine regarding its photocurable dermal filler, suggesting it could be a game changer for facial plastic surgery.
CollPlant's collaboration with AbbVie is progressing, with AbbVie collecting data from clinical trials and a recent $2 million payment received by CollPlant following a development achievement.
The regenerative breast implant program is showing promising preclinical results, with successful tissue integration and vascularization observed in one study arm.
CollPlant's recombinant human collagen technology is in demand, with ongoing discussions with various companies interested in accessing this technology.
CollPlant Biotechnologies Ltd (NASDAQ:CLGN) reported a significant decrease in GAAP revenues for 2024, with $515,000 compared to $11 million in 2023, primarily due to a $10 million milestone payment from AbbVie in 2023.
The company experienced a GAAP gross loss of $1.1 million for the year ended December 31, 2024, compared to a gross profit of $9 million in 2023.
GAAP net loss for 2024 was $16.6 million, significantly higher than the $7 million net loss in 2023, attributed to the absence of a large milestone payment received in the previous year.
Cash used in operating activities increased to $14.1 million in 2024 from $2.8 million in 2023, indicating higher operational expenses.
The company's cash runway is expected to last only until the second quarter of 2026, raising concerns about long-term financial sustainability without additional revenue streams or partnerships.
Q: When can we expect an update from AbbVie on their studies, and are there any anticipated milestone payments in 2025? A: AbbVie is currently reviewing interim results from the first cohort of patients in their dermal filler clinical trials. The next steps will be determined by AbbVie, and we will update the market accordingly. Recently, we received a $2 million payment from AbbVie following a development achievement, but we cannot estimate when the next milestone payment will occur. - Eran Rotem, Deputy CEO and CFO
Q: Can you provide details on the market potential and revenue expectations for the VergenixSTR product in Europe and Asia? A: VergenixSTR is intended for treating tendinopathy and has a market potential of 1% to 3% of the population. We are establishing a distribution network in Europe and Asia, and each country requires regulatory approval. We expect to start seeing sales next year, with the product offering a significant advantage over steroid injections. - Yehiel Tal, CEO
Q: What is the company's current cash position and burn rate, and how long will it last? A: As of December 31, 2024, we had $11.9 million in cash, not including a recent $2 million payment from AbbVie. Our cost reduction plan does not materially impact main development programs. We expect our cash to support operations through the second quarter of 2026, under conservative assumptions. - Eran Rotem, Deputy CEO and CFO
Q: What are the upcoming catalysts for CollPlant's proprietary programs? A: We plan to potentially launch a clinical trial for our photocurable dermal and soft tissue filler within two years. For our regenerative breast implant program, we aim to optimize the implant characteristics and clinical protocol to reach clinical trial readiness. We will also expand the distribution network for VergenixSTR in Europe and Asia and broaden our bioinks product offerings. - Yehiel Tal, CEO
Q: How is CollPlant planning to expand sales of its rhCollagen product? A: We plan to expand sales of our rhCollagen to selected customers that align with our business model. This expansion is part of our strategy to support various bioprinting technologies and advance potential partnership discussions. - Yehiel Tal, CEO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
1 Brilliant Artificial Intelligence (AI) Stock That Will Be Worth More Than Apple by 2030
Key Points AWS and advertising drive Amazon's growth. Apple hasn't released an innovative product or feature in some time. 10 stocks we like better than Amazon › Apple is the world's third-largest company by a wide margin, with a $1 trillion gap between it and fourth-place Alphabet . However, I think several companies are slated to pass Apple in market share over the next five years, including fifth-place Amazon (NASDAQ: AMZN), which is valued at around $2.4 trillion compared to Apple's $3.5 trillion. That's a wide gap to make up in five years, but looking at Amazon's growth tailwinds versus Apple's makes it fairly clear that Amazon is the much better stock pick. Amazon has two business units driving profit growth Apple's business is fairly straightforward; it's the leading consumer tech brand and generates significant revenue selling iPhones and other products in the Apple ecosystem. Amazon is a bit more complex, as it has the online store that most investors are familiar with, but that's not the best reason to invest in it. Although its online stores division posted the best quarter in a long time (revenue rose 11% year over year), the real stars of the show are Amazon Web Services (AWS) and its advertising services division. AWS is Amazon's cloud computing platform, and it is seeing strong demand fueled by the migration of traditional workloads to the cloud, as well as by new artificial intelligence (AI) workloads. AWS grew revenue by 17% year over year in Q2, which is strong growth considering it generated nearly $31 billion in revenue during the quarter. However, AWS's primary competitors (Microsoft's Azure and Google Cloud) posted stronger growth rates in their corresponding quarters, so investors are worried about AWS's long-term ability to perform in this sector despite its being the market-share leader. AWS will likely continue to underperform its peers due to its size, but 17% growth is nothing to sneer at. AWS is also a large part of Amazon's profit picture. In Q2, it accounted for 53% of Amazon's operating profits despite accounting for only 18% of revenue. Analysts still expect cloud computing to grow rapidly over the next few years, and if Amazon surpasses Apple in market cap, this will be a primary reason why. Advertising services is Amazon's fastest-growing segment, with revenue rising 23% year over year, an acceleration over previous quarters' growth rate. Amazon has one of the most lucrative places to advertise on the internet, as consumers are already coming to their platform to make purchases. Paying to place a product at the top of an Amazon search almost guarantees increased sales. This is worth a lot to its advertising clients and will be a key part of Amazon's investment thesis over the next few years. Amazon's margins are rising Amazon isn't a revenue growth story; it's a profit growth story. The rise of high-margin businesses like AWS and advertising services has helped Amazon boost its profit margins over the past few years. AMZN Profit Margin data by YCharts With its two high-margin business segments growing faster than other parts of its business, Amazon will naturally have elevated profit growth rates. In Q2, Amazon's operating income rose 31% year over year. Contrast that with Apple, whose Q3 FY 2025 (ending June 28) operating income increased by 11%. Amazon's profit growth rate is much faster. Over five years, a 30% growth rate will increase its operating income by 271% while an 11% growth rate increases operating income by only 69%. That would be enough to drive Amazon's profits higher than Apple's, propelling it to surpass it in size along the way. Amazon is an excellent stock pick for the next five years and a no-brainer buy at today's prices. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Keithen Drury has positions in Alphabet and Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 1 Brilliant Artificial Intelligence (AI) Stock That Will Be Worth More Than Apple by 2030 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
an hour ago
- Business Insider
APP vs. ACHR vs. RGTI: Which ‘Strong Buy' Growth Stock Has the Highest Upside Potential, According to Wall Street?
The optimism around artificial intelligence and many breakthrough technologies, including air taxis and quantum computing, is driving several growth stocks higher. Using TipRanks' Stock Comparison Tool, we placed AppLovin (APP), Archer Aviation (ACHR), and Rigetti Computing (RGTI) against each other to find the growth stock with the highest upside potential, according to analysts. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AppLovin Corporation (NASDAQ:APP) Stock Ad tech company AppLovin provides AI-enhanced solutions that enable businesses to reach, monetize, and grow their audiences. The company recently reported market-beating second-quarter results, defying certain allegations made by three short sellers – Fuzzy Panda Research, Muddy Waters, and Culper Research. AppLovin is witnessing strong demand for its artificial intelligence (AI)-powered technology that enables advertisers to target mobile game users more effectively. The company impressed investors with a 77% year-over-year growth in its Q2 revenue to $1.26 billion and a 168.5% jump in adjusted earnings per share (EPS) to $2.39. Looking ahead, AppLovin stands to gain from the legal battle between Apple (AAPL) and Epic Games, as changes to the iPhone maker's App Store monetization policies are expected to benefit mobile advertisers and app developers. What Is the Target Price for AppLovin Stock? Following the Q2 print, Loop Capital analyst Rob Sanderson reiterated a Buy rating on AppLovin stock with a price target of $650. The 5-star analyst highlighted that the company reported another beat-and-raise quarter, though somewhat more muted in terms of the magnitude of upside seen in recent quarters. Sanderson noted that the majority of the 9% sequential growth in Q2 revenue was driven yet again by gaming customers, as the company 'methodically refines its offering for web-based (e-commerce) advertisers.' He views the Q3 revenue guidance as conservative. Overall, AppLovin stock scores a Strong Buy consensus rating based on 17 Buys and three Hold recommendations. The average APP stock price target of $524.78 indicates about 20% upside potential from current levels. AppLovin stock has risen more than 35% year-to-date. Archer Aviation (NYSE:ACHR) Stock Archer Aviation is a maker of electric vertical takeoff and landing (eVTOL) aircraft. ACHR stock is flat on a year-to-date basis, but has rallied more than 163% over the past year due to the optimism around eVTOL technology. The Trump administration's executive order to accelerate VTOL development and commercialization, the announcement of multiple partnerships with major companies like United Airlines (UAL), and selection as the official air taxi service for the 2028 Los Angeles Olympics have bolstered Wall Street's optimism about ACHR's growth potential. Archer Aviation is a pre-revenue company. It recently reported a larger-than-anticipated loss for Q2 2025 due to higher spending to support its growth. Nonetheless, Wall Street is optimistic about ACHR due to solid progress on key deals, including the UAE program, and its robust cash position of $1.7 billion that will enable growth investments. Is ACHR a Good Stock to Buy? In reaction to the Q2 results, Cantor Fitzgerald analyst Andres Sheppard reiterated a Buy rating on Archer Aviation stock with a price target of $13. The 4-star analyst is encouraged by ACHR's plans to boost manufacturing and the production of the six additional aircraft (three of which are in final assembly), which management stated will 'either be used for FAA Certification or initial commercialization deployment.' Sheppard continues to expect the UAE to be the initial market for ACHR's eVTOL commercialization, with the company reaffirming its timeline to commercialize in the fourth quarter of 2025. The analyst also cheered Archer Aviation's expansion into hybrid VTOLs, which he believes will de-risk its business. Additionally, he continues to view the partnerships with the Department of Defense (DoD), United Airlines, and Stellantis (STLA) as important differentiators. He noted that ACHR now has the highest liquidity in the industry and has been gaining momentum by expanding its order book via its launch edition program, which aims to commercialize in select markets prior to FAA Certification. Sheppard is also optimistic about ACHR's air taxi service deal for the LA 2028 Olympics. With six Buys and two Holds, Wall Street has a Strong Buy consensus rating on TipRanks. The average ACHR stock price target of $12.06 indicates about 23% upside potential from current levels. Rigetti Computing (NASDAQ:RGTI) Stock Rigetti Computing, which boasts of being a pioneer in full-stack quantum-classical computing, recently reported underwhelming results for the second quarter of 2025. RGTI's Q2 revenue declined by about 42% year-over-year to $1.8 million, while net loss per share increased to $0.13 from $0.07 in the prior-year quarter. Despite the dismal results, RGTI remains upbeat about its growth opportunities in the lucrative quantum computing space. The company ended the second quarter with $571.6 million in cash, cash equivalents, and available-for-sale investments (with no debt), thanks to gross proceeds of $350 million from an equity offering completed in June. Rigetti is confident about the scheduled release of its 100+ qubit chiplet-based system at 99.5% median two-qubit gate fidelity before the end of this year. Is RGTI Stock a Buy, Sell, or Hold? Following the Q2 results, Benchmark analyst David Williams increased the price target for Rigetti Computing stock to $20 from $14 and reaffirmed a Buy rating, noting continued progress on the company's chiplet-based scaling strategy. The 5-star analyst highlighted that the company remains on schedule to deliver its 100-qubit multi-chiplet QPU, an important milestone on the path to quantum advantage. He added that the recent release of the Cepheus-1 system successfully met the fidelity target while significantly reducing error rates. It marked the launch of the industry's largest multi-chip quantum processor, establishing the scalability of Rigetti's architecture. Overall, Williams believes that these advancements strengthen Rigetti's roadmap toward a 1,000+ qubit system. Although management continues to see a 3 to 4-year timeline to reach the quantum advantage threshold, Williams thinks that there are meaningful opportunities to generate revenue well ahead of these targets. Rigetti Computing earns Wall Street's Strong Buy consensus rating based on seven Buys and one Hold recommendation. The average RGTI stock price target of $18.71 implies 12.4% upside potential. RGTI stock has risen 9.1% year-to-date. Conclusion Wall Street is bullish about the growth prospects of AppLovin, Archer Aviation, and Rigetti Computing. Currently, analysts see higher upside potential in Archer Aviation stock than in the other two growth stocks. Investors need to bear in mind that Archer Aviation is a high-risk, high-reward investment, with strong prospects in the eVTOL aircraft space.
Yahoo
an hour ago
- Yahoo
Dow futures rise as updates this week from the Fed and top retailers will test Wall Street's big rally
Wall Street is heading into a pivotal week, with stocks riding high on expectations that the Federal Reserve will cut rates next month and signs that tariffs aren't weighing on the economy as much as feared, so far. But minutes from the Fed's last meeting, Jerome Powell's Jackson Hole speech, and retail earnings will put the market's views to the test. U.S. stock futures pointed higher on Sunday evening ahead of a critical stretch for markets as investors brace for fresh clues on rate cuts and tariffs. Futures tied to the Dow Jones Industrial Average rose 48 points, or 0.11%. S&P 500 futures were up 0.12%, and Nasdaq futures added 0.18%. The yield on the 10-year Treasury was flat at 4.322%. The U.S. dollar was down 0.07% against the euro but up 0.07% against the yen. Gold fell 0.25% to $3,374.10 per ounce. U.S. oil prices dropped 0.27% to $62.63 per barrel, and Brent crude fell 0.41% to $65.58. Energy markets will also be in focus this week amid continued diplomacy to end Russia's war on Ukraine as harsher U.S. sanctions on Moscow could target its oil exports, though President Donald Trump refrained from announcing any fresh penalties after ceasefire talks Friday failed to produce a deal. Stocks have notched two consecutive weekly gains, with the S&P 500 hitting a fresh all-time high last week. That's as corporate earnings have continued to come in strong and as the latest inflation readings were mixed but still haven't set off panic about the effect of tariffs. With the labor market also looking weaker, Wall Street overwhelmingly sees the inflation data giving the Federal Reserve a green light to resume rate cuts next month, further fueling market optimism. But those views will be tested this week. On Wednesday, the Fed will release minutes from its policy meeting in July, when central bankers kept rates steady though two officials dissented. The details should show how much debate occurred and to what extent other policymakers were leaning a certain way. Then the main attraction will take place on Friday, when Fed Chair Jerome Powell will deliver a speech at a gathering in Jackson Hole, Wyo. The annual event previously has served as an opportunity for policymakers to tease forthcoming rate moves. Last year, Powell signaled a pivot to cuts, saying 'the time has come for policy to adjust' and that 'my confidence has grown that inflation is on a sustainable path back to 2%.' But he may not drop big hints this year, potentially setting up Wall Street for major disappointment. Meanwhile, earnings season is winding down, but the coming week will feature several top retailers. Home Depot reports Tuesday, with Lowe's and Target due on Wednesday. Walmart will put out its numbers on Thursday. Their quarterly updates will provide new insights into how much tariffs are affecting prices and who is picking up the extra costs. The precise impact of tariffs on inflation remains somewhat of a mystery. While companies may be absorbing much of the tariff costs for now, it's not clear how much longer they can keep it up and how much consumers will be able to shoulder later. If the retail giants keep eating tariff costs, that will show up on the bottom line and in their guidance. Citi doesn't expect consumers to get hit with big price hikes in the future, even as more levies are expected to roll out. 'Softer demand means firms will have difficulty passing tariff costs on to consumers,' chief US economist Andrew Hollenhorst said in a note. 'While some firms might still attempt to slowly increase prices in coming months, the experience so far suggests these increases will be modest in size. This should reduce concerns about upside risk to inflation and increase concerns that decreased profit margins will cause firms to pullback on hiring.' This story was originally featured on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
